A shareholder class action against Insulet Corp. (NASDAQ: PODD) alleges defective manufacturing controls misled investors, with a lead plaintiff deadline of Aug. 31.
Back
Insulet faces securities class action with Aug 31 lead plaintiff deadline
A shareholder class action against Insulet Corp. (NASDAQ: PODD) alleges defective manufacturing controls misled investors, with a lead plaintiff deadline of Aug. 31.
The lawsuit, filed in the U.S. District Court for the District of Massachusetts, claims Insulet's manufacturing controls and procedures were defective, creating a foreseeable risk that Omnipod products would violate safety regulations or pose injury risk, Holzer & Holzer said.
The alleged problems emerged through two voluntary Medical Device Corrections. On March 12, 2026, Insulet recalled specific lots of Omnipod 5 Pods after identifying a manufacturing issue, sending shares down $16.23, or 6.88 percent, to $219.84 on March 13. On May 26, Insulet disclosed a second correction covering Omnipod 5, Omnipod Dash and Omnipod Eros pods that could cause insulin under-delivery, and the stock fell $7.79, or 5.07 percent, to $146.01 the next day.
The class covers investors who bought Insulet securities between Feb. 21, 2025 and May 26, 2026. Investors seeking lead plaintiff status must move the court by Aug. 31, 2026. The case, docketed 26-cv-13062, is one of several filed by firms including Faruqi & Faruqi, Pomerantz, Robbins and Rosen Law.
The complaint alleges Insulet and its executives violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 by making false or misleading statements about its business, operations and compliance policies. The company develops and sells insulin delivery systems, including the Omnipod 5 automated insulin delivery system, which integrates with a third-party continuous glucose monitor.
Insulet did not immediately respond to a request for comment. The lead plaintiff, typically the investor with the largest financial interest in the relief sought, directs the litigation on behalf of the class; investors who do not seek the role can still share in any recovery.
The two corrections wiped roughly $24 in combined per-share value from the stock, showing the market's sensitivity to product-safety disclosures at a company whose revenue depends on a single device franchise. Investors will watch whether Insulet faces further regulatory scrutiny or additional corrections before the Aug. 31 lead plaintiff deadline.
This article is for informational purposes only and does not constitute investment advice.
[1] PODD INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of the August 31, 2026 Lead Plaintiff Deadline in the Insulet Corporation Securities Class Action[2] PODD INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026[3] Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and ... | National | reflector.com[4] Insulet Corporation Stockholders May Be Eligible to Lead the Class Action Against PODD; Contact Robbins LLP Before the August 31, 2026 Deadline for Information - The Globe and Mail[5] ... COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel...August...
